Gapping up
In reaction to strong earnings/guidance: BPMX +11.7%, NDSN +7.9%, FSFR +1.7%, RICK +1%, ESRX +0.8%
M&A news: NSR +20.4% (to be acquired for $33.50 per share by Golden Gate Capital)
Other news:
- VCEL +65.4% (FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee)
- BCLI +27.3% (announces new data from its Phase 2 study of NurOwn)
- REXX +19.2% (announces that Nasdaq has accepted Rex Energy's request for continued listing )
- SKIS +15.8% (announced USCIS approved the first I-526 Petition submitted by an investor in Mount Snow's EB-5 offering, allowing the funds raised in the offering to be released from escrow immediately)
- PLX +14.7% (Co received a letter from Fundação Oswaldo Cruz detailing intended purchases by the Brazilian Ministry of alfataliglicerase to treat Gaucher patients in Brazil of approximately $24 mln)
- ADHD +11.7% (announces it recently held a face-to-face meeting with the FDA to discuss their decision to place a full clinical hold on the development programs of Metadoxine Extended Release)
- ENT +10.7% (Global Eagle discloses in a filing that they entered into a new supply & services agreement with Southwest Airlines)
- DRWI +5.5% (receives extension from NASDAQ until April 17, 2017 to regain compliance)
- VTGN +5.3% (signs an exclusive sublicense agreement with BlueRock Therapeutics for VistaGen's rights)
- DSX +5.2% (Ironwood Trading discloses a 22.2% active stake)
- PRTO +4% (modestly rebounding following yesterday's weakness)
- RDHL +3.1% (Co and IntelGenx (IGXT) sign an exclusive license agreement with Pharmatronic for the commercialization of RIZAPORT in South Korea)
- ONVO +2.1% (announces an exclusive distributor agreement with Cosmo Bio for its NovoView Preclinical Services in Japan)
- WNC +1.6% (ticking higher, reinstates dividend; intends to pay a quarterly dividend of $0.06/share )
- VRX +1.2% (Pershing files amended 13D disclosing 7.8% active stake that reflects the sale of more than 3 mln shares)
- DBD +1.2% (Atlantic Investment discloses 5.1% active stake)
- H +0.6% (announces new authorization of $250 million in share repurchases)
Analyst comments:
- NI +2.2% (upgraded to Buy from Neutral at Citigroup)
- NVDA +1.3% (upgraded to Buy from Hold at Evercore ISI )
- KLAC +1.3% (upgraded to Strong Buy at Needham)
- FFIV +0.8% (upgraded to Buy from Neutral at Citigroup)
- AKAM +0.8% (upgraded to Outperform from Perform at Oppenheimer)